Enable valid comparisons between cohorts |
33 |
Subject to scientific validation |
33 |
Achieve high intra- and inter-rater reliability |
32 |
User-friendly and easy to apply |
30 |
Include several relevant regions of brain |
29 |
Should not require specialised equipment |
29 |
Record association with other pathological findings |
25 |
Avoid prior assumptions about biological relevance of CAA (i.e. avoid assessing severity according to the absence of presence of findings such as infarcts or haemorrhage) |
25 |
Assessment of CAA based on labelling with antibodies |
24 |
Highly sensitive to detection of mild CAA |
22 |
Relate score to clinical as well as pathological features |
19 |
Based on same blocks as used for CERAD assessment |
18 |
Demonstrate amyloid nature of vascular deposits, in addition to Aβ on immunohistochemistry |
15 |